NASDAQ · BMRN

BioMarin Pharmaceuticals Inc.

$59.33 +$0.46 (+0.78%) 1D After hours
Charting by TradingView

Key Metrics

$11.38B
Market cap
42.34×
P/E · TTM
$3.24B
Revenue · TTM
$268.74M
Net income
EPS · TTM $1.37
Dividend yield —
Free cash flow $767.06M
Beta · 1Y 0.37
EBITDA · TTM $459.49M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 29
    The stock moved +8.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$11.38B
Enterprise value$10.59B
Shares outstanding193.3M
52-wk range$49.26 – $66.28
Avg volume · 20D1.6M
Net cash $792.15M
Book value / share$31.62
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About BioMarin Pharmaceuticals Inc.
IPO dateJul 23, 1999
Employees3221

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E42.34
P/S3.51
P/FCF14.83
EV/EBITDA23.04
EV/Sales3.27
Graham №$31.19

Profitability

Gross —
Operating 11.9%
Net 8.3%
FCF 23.7%
ROE / ROIC 4.5% · 5.0%

Financial Health

Current ratio5.81
Quick ratio4.20
Debt / equity0.23
Debt / EBITDA 3.11
Net cash $792.15M
Working capital$3.81B

Cash Flow · TTM

Operating CF $874.25M
Capex −$107.19M
Free cash flow $767.06M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

4.0
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$31.19 vs $59.33
Trades 1.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings